Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ezogabine

FDA-approved product (tablet, oral), marketed as Potiga.

Registered studies
32
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Ezogabine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Epilepsy
  • Seizure

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antiepileptics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA28.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli32.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae11.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

32registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ezogabine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ezogabine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE

    NCT04912856 · start 2021-08-17

    Registered record
    Registry ID
    NCT04912856
    Conditions
    Epilepsy; Epilepsy in Children; Epilepsy; Seizure; Disease; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Epileptic Syndromes
    Interventions
    XEN496
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2021-08-17
    Completion
    2023-11-17
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy; Epilepsy in Children; Epilepsy; Seizure +5 more
    InterventionXEN496
    PhasePhase 3
    Registry statusTerminated

  • XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

    NCT04639310 · start 2021-03-29

    Registered record
    Registry ID
    NCT04639310
    Conditions
    Epilepsy; Epilepsy in Children; Epilepsy; Seizure; Disease; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Epileptic Syndromes
    Interventions
    XEN496; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2021-03-29
    Completion
    2023-05-16
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy; Epilepsy in Children; Epilepsy; Seizure +5 more
    InterventionXEN496; Placebo
    PhasePhase 3
    Registry statusTerminated

  • Study to Treat Major Depressive Disorder With a New Medication

    NCT03043560 · start 2017-09-25

    Registered record
    Registry ID
    NCT03043560
    Conditions
    Depressive Disorder; Anhedonia
    Interventions
    Ezogabine; Placebos
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-09-25
    Completion
    2019-08-30
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepressive Disorder; Anhedonia
    InterventionEzogabine; Placebos
    PhasePhase 2
    Registry statusCompleted

  • Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study.

    NCT02727101 · start 2015-11

    Registered record
    Registry ID
    NCT02727101
    Conditions
    Epilepsy
    Interventions
    perampanel
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2015-11
    Completion
    2017-07
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy
    Interventionperampanel
    PhasePhase 4
    Registry statusTerminated

  • Clinical Trial of Ezogabine (Retigabine) in ALS Subjects

    NCT02450552 · start 2015-06

    Registered record
    Registry ID
    NCT02450552
    Conditions
    Amyotrophic Lateral Sclerosis
    Interventions
    Ezogabine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-06
    Completion
    2018-02
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyotrophic Lateral Sclerosis
    InterventionEzogabine; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Potential Advantages of Robotic Total Gastrectomy in Advanced Middle-Upper Gastric Cancer: A Multicenter Propensity Score Matching Analysis

    NCT06941168 · start 2015-01

    Registered record
    Registry ID
    NCT06941168
    Conditions
    Advanced Gastric Cancer
    Interventions
    Robotic Total Gastrectomy and Laparoscopic Total Gastrectomy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-01
    Completion
    2024-08
    Enrolment
    1,099

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Gastric Cancer
    InterventionRobotic Total Gastrectomy and Laparoscopic Total Gastrectomy
    PhaseNot recorded
    Registry statusCompleted

  • Study to Treat Major Depressive Disorder (MDD) With a New Medication

    NCT02149836 · start 2014-08

    Registered record
    Registry ID
    NCT02149836
    Conditions
    Major Depressive Disorder; Depression
    Interventions
    ezogabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-08
    Completion
    2016-12
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder; Depression
    Interventionezogabine
    PhasePhase 2
    Registry statusCompleted

  • A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures

    NCT01777139 · start 2013-04-11

    Registered record
    Registry ID
    NCT01777139
    Conditions
    Epilepsy
    Interventions
    Retigabine IR
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-04-11
    Completion
    2017-09-13
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy
    InterventionRetigabine IR
    PhasePhase 3
    Registry statusCompleted

  • Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study

    NCT01823159 · start 2013-04

    Registered record
    Registry ID
    NCT01823159
    Conditions
    Epilepsy
    Interventions
    retigabine; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-04
    Completion
    2014-01
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy
    Interventionretigabine; placebo
    PhasePhase 3
    Registry statusCompleted

  • An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures

    NCT01607346 · start 2013-03-27

    Registered record
    Registry ID
    NCT01607346
    Conditions
    Epilepsy
    Interventions
    ezogabine/retigabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2013-03-27
    Completion
    2016-11-16
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy
    Interventionezogabine/retigabine
    PhasePhase 4
    Registry statusTerminated

  • REMS Retigabine Study

    NCT01938560 · start 2013-02

    Registered record
    Registry ID
    NCT01938560
    Conditions
    Epilepsy
    Interventions
    Survey Responses
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-02
    Completion
    2013-05
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy
    InterventionSurvey Responses
    PhaseNot recorded
    Registry statusCompleted

  • Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures

    NCT01721317 · start 2012-12-19

    Registered record
    Registry ID
    NCT01721317
    Conditions
    Seizures
    Interventions
    Ezogabine/Retigabine IR; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2012-12-19
    Completion
    2013-06-20
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeizures
    InterventionEzogabine/Retigabine IR; Placebo
    PhasePhase 4
    Registry statusTerminated

  • Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects

    NCT01691872 · start 2012-10-10

    Registered record
    Registry ID
    NCT01691872
    Conditions
    Epilepsy, Partial
    Interventions
    Retigabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2012-10-10
    Completion
    2012-10-18
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy, Partial
    InterventionRetigabine
    PhasePhase 1
    Registry statusWithdrawn

  • Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS

    NCT01668654 · start 2012-09-04

    Registered record
    Registry ID
    NCT01668654
    Conditions
    Epilepsy
    Interventions
    retigabine/ezogabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2012-09-04
    Completion
    2013-06-18
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy
    Interventionretigabine/ezogabine
    PhasePhase 3
    Registry statusTerminated

  • Trobalt™ Products Risk Survey

    NCT01721213 · start 2012-09

    Registered record
    Registry ID
    NCT01721213
    Conditions
    Epilepsy
    Interventions
    Trobalt™
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-09
    Completion
    2013-12
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy
    InterventionTrobalt™
    PhaseNot recorded
    Registry statusCompleted